share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股变动声明
SEC announcement ·  03/22 17:48
Moomoo AI 已提取核心信息
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG's Chief Executive Officer, Samarth Kulkarni, has engaged in a transaction involving the company's stock on March 20, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action reflects the CEO's dealings with the company's non-derivative securities. Investors are advised to note the involvement of a high-level executive in the company's stock transactions, which may be indicative of the company's internal confidence and future prospects.
CRISPR Therapeutics AG首席执行官萨玛斯·库尔卡尼已于2024年3月20日参与了一项涉及该公司股票的交易。该交易的细节，包括所涉及的股票数量和交易价格，尚未在公告中披露。该行动反映了首席执行官与公司非衍生证券的交易。建议投资者注意高级管理人员参与公司的股票交易，这可能表明公司的内部信心和未来前景。
CRISPR Therapeutics AG首席执行官萨玛斯·库尔卡尼已于2024年3月20日参与了一项涉及该公司股票的交易。该交易的细节，包括所涉及的股票数量和交易价格，尚未在公告中披露。该行动反映了首席执行官与公司非衍生证券的交易。建议投资者注意高级管理人员参与公司的股票交易，这可能表明公司的内部信心和未来前景。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息